Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,602 recruiting studies in this area right now.
By phase
- Not applicable9,790
- Phase 24,449
- Phase 12,736
- Phase 1/Phase 21,687
- Phase 31,397
- Phase 2/Phase 3280
- Phase 4263
Top conditions
- Breast Cancer1,227
- Cancer661
- Prostate Cancer654
- Colorectal Cancer491
- Lung Cancer424
- Ovarian Cancer338
- Multiple Myeloma332
- Gastric Cancer296
- Acute Myeloid Leukemia292
- Pancreatic Cancer290
- Hepatocellular Carcinoma283
- Solid Tumor257
- Advanced Solid Tumor255
- Cervical Cancer232
- Head and Neck Cancer227
- Endometrial Cancer206
- Advanced Solid Tumors193
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center450
- Fudan University313
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center288
- National Cancer Institute (NCI)285
- Mayo Clinic240
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center147
- AstraZeneca134
- University Health Network, Toronto125
Where studies are running
- California1,424
- Texas638
- Arizona513
- Florida448
- Alabama420
- New York409
- Massachusetts343
- Maryland329
- New Jersey269
- Pennsylvania241
Recruiting studies20,602 total
- NCT07100210RecruitingPhase 1
Study of a new drug for advanced solid tumors that haven't responded to treatment
This trial tests a new drug, IL-22BP/LNP, for people with advanced solid tumors (like soft tissue sarcoma, head and neck cancer, melanoma) that have worsened after standard treatments. The main goals are to see if the drug is safe and tolerable, and to learn if it might help shrink or slow the cancer.
Chengdu, SichuanAges 18–70 - NCT07561437RecruitingEarly Phase 1
NK521 infusion for advanced cancer with fluid buildup
This early-stage trial tests NK521, a new immunotherapy infusion, for patients with advanced solid tumors (like liver, stomach, or colon cancer) that have spread and caused fluid buildup in the belly. The goal is to see if NK521 can help shrink tumors and improve survival when standard treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT07561554RecruitingPhase 1
New BRAF-Targeting Drug for Advanced Solid Tumors
This is an early-stage study testing a new investigational drug (HSK42360-Na) designed to target a specific genetic mutation (BRAF V600) found in some advanced or metastatic cancers. The goal is to see if this drug is safe and effective for patients whose cancers have grown despite prior treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07046650RecruitingPhase 2
Cisplatin plus gemcitabine for rare tumors after PD-1 therapy
This trial tests a combination of two chemotherapy drugs, cisplatin and gemcitabine, for people with certain rare cancers that no longer respond to a type of immunotherapy called PD-1 inhibitors. The goal is to see how well this treatment works and what side effects it may cause.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05784428Recruiting
Radiation “spot treatments” for a few metastatic or worsening spots
This trial compares giving stereotactic ablative radiotherapy as one larger treatment plan versus several smaller plans for people who have only a few cancer spots (or a few spots that are worsening). It may help control metastatic disease while aiming to protect surrounding healthy organs.
Kelowna, British ColumbiaAges 18 years+ - NCT06494514Recruiting
New chemo combo with immunotherapy and radiation for advanced pancreatic cancer
This trial compares two different chemotherapy combinations, each paired with immunotherapy and radiation, as the first treatment for locally advanced pancreatic cancer. It aims to see which combination works better.
Nanjing, JiangsuAges 18 years+ - NCT07331155RecruitingPhase 2
LBL-024 combo for advanced esophageal cancer
This trial tests a new drug combination for advanced solid tumors, specifically esophageal cancer. It may help people whose cancer has not responded to other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05773937RecruitingPhase 1
Study drug for advanced solid tumors after prior treatments
This Phase 1 study tests 9MW2821 in people with advanced solid cancers that have grown despite earlier treatment. It aims to find the safest dose and learn how the drug works, and it may be an option if you can provide tumor tissue and meet key health criteria.
Beijing, Beijing MunicipalityAges 18–80 - NCT07327632RecruitingEarly Phase 1
Testing IBI3026 for advanced solid tumors
This study tests a new drug called IBI3026 for people with advanced solid tumors that cannot be surgically removed or have spread. The goal is to see if it is safe and helps control the cancer.
Chengdu, SichuanAges 18 years+ - NCT05860868RecruitingPhase 3
Two versus three chemo treatments before radiation for nasopharyngeal cancer
This Phase 3 trial compares giving two cycles versus three cycles of chemotherapy before other treatment for locally advanced nasopharyngeal cancer. It may help find which schedule works best to control the cancer while managing side effects.
Guangzhou, Other (Non U.s.)Ages 18–65 - NCT07549100Recruiting
Tislelizumab plus chemotherapy for advanced esophageal cancer
This trial tests whether combining tislelizumab (an immunotherapy drug) with chemotherapy can shrink advanced esophageal cancer before surgery. The goal is to help patients whose tumors are too large or invasive to operate on initially.
Jinan, ShandongAges 18–75 - NCT05759572RecruitingPhase 2
Apatinib plus hormone therapy for advanced breast cancer
This Phase 2 study tests whether apatinib combined with a CDK4/6 inhibitor and hormone therapy can better control advanced hormone receptor–positive, HER2-negative breast cancer. It may help shrink tumors or slow their growth, especially in cases that can’t be fully treated with surgery or radiation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07109401RecruitingPhase 2
Immunotherapy for early-stage small cell lung cancer that can be removed with surgery
This trial tests whether giving immunotherapy before and after surgery can help people with limited-stage small cell lung cancer. It is for patients whose cancer has not spread widely and can be completely removed by surgery.
ShanghaiAges 18–75 - NCT07110103RecruitingPhase 2
Golidocitinib with immunotherapy for extensive-stage small cell lung cancer
This trial tests a combination of golidocitinib (a targeted pill) and a PD-1 inhibitor (a type of immunotherapy) as a maintenance treatment after initial chemotherapy. It may help keep your lung cancer from growing longer.
BeijingAges 18 years+ - NCT05205109RecruitingPhase 1
Testing a new melanoma drug alone and with pembrolizumab
This early-stage trial tests ATG 037 to see if it’s safe and how it works in the body, as well as whether it may help people with advanced melanoma. It compares treatment given alone and treatment given together with pembrolizumab, especially in melanoma that has progressed after prior immunotherapy.
Sydney, New South WalesAges 18 years+ - NCT03736889RecruitingPhase 2
Tislelizumab for MSI-H or dMMR solid tumors after prior treatment
This trial studies tislelizumab, an immune treatment that blocks PD-1, in people with MSI-H or dMMR solid tumors that cannot be fully removed or have spread, after other treatment has already been tried. It may help your immune system recognize and fight the cancer.
Hefei, AnhuiAges 18 years+ - NCT05749900RecruitingPhase 1/Phase 2
First-line antibody, chemo, and immunotherapy for HER2 bile duct cancer
This trial studies a combination of trastuzumab (an antibody), gemcitabine and cisplatin (chemo), plus nivolumab (immunotherapy) as the first treatment for advanced HER2-positive biliary tract cancer. It may help shrink tumors and improve outcomes by targeting HER2 and boosting the immune system.
SeoulAges 19 years+ - NCT05575323Recruiting
Same-day radiation and stabilization for spine metastases
This trial tests whether giving focused radiation (SBRT) on the same day as spine surgery to stabilize the spine helps control symptoms from spinal metastases. It may help reduce pain and improve stability, especially when tumors threaten or affect the spine’s strength.
UtrechtAges 18 years+ - NCT07113691RecruitingPhase 1
Experimental drug plus radiation and immunotherapy for lung cancer
This study tests a combination of three treatments for extensive-stage small cell lung cancer that has worsened after initial chemotherapy: an experimental pill, focused radiation (SBRT), and an immunotherapy drug. The goal is to see if this triple therapy can help the immune system fight the cancer more effectively.
New Haven, ConnecticutAges 18 years+ - NCT07156903Recruiting
Understanding patient and caregiver needs during prostate cancer radiation
This study asks people with prostate cancer and their caregivers about their needs during and after radiation treatment. It uses interviews to learn how to better support patients and families.
BerlinAges 18 years+ - NCT07116161Recruiting
Exercise and counseling for fatigue in female breast cancer patients
This trial tests if combining exercise with cognitive behavioral therapy (counseling) can help reduce fatigue in women with breast cancer. You may be able to join if you have completed your initial treatments and still feel tired.
SingaporeAges 21 years+ - NCT05741359RecruitingPhase 1
Study of BRL-201 for hard-to-treat aggressive B-cell lymphoma
This Phase 1 study tests BRL-201 (an anti-CD19 treatment) for safety and early signs of effectiveness in adults with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. It may help people whose lymphoma has returned or not responded to prior treatments.
Wuhan, HubeiAges 18 years+ - NCT07536789RecruitingPhase 2
Testing MRG003 for Advanced Liver Cancer After Prior Treatment
This trial tests a new drug called becotatug vedotin (MRG003) for patients with advanced liver cancer that has progressed despite previous immunotherapy. The drug is designed to target cancer cells while potentially causing less harm to healthy tissue.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07321574RecruitingPhase 2
Testing ABP1011T for advanced solid tumors
This trial tests an experimental pill called ABP1011T for people with advanced solid tumors that are no longer responding to standard treatments. It is especially focused on small cell lung cancer and other cancers that might be sensitive to this drug. The goal is to see if the pill can shrink tumors or slow their growth.
Luoyang, HenanAges 18–75
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,602 recruiting oncology studies from the U.S. registry right now, out of 31,289 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.